Education
About Us
Working with TipRanks
Follow Us
Bruker Corporation (BRKR)
:BRKR
Top Page
Bruker
(NASDAQ:BRKR)
Rating:50Neutral
Price Target:
$31.00
▼(-3.34% Downside)
Positive Factors
Cost Savings
A $100 million+ cost saving program is expected to bolster operating margins in 2026, helping BRKR to deliver significant margin expansion and earnings growth even with flat revenue.
Currency Impact
Weakening of the USD drove FX to a +2.5% tailwind to sales compared to the prior assumption of a +1% tailwind.
Negative Factors
Demand Pressure
BRKR continues to face broad-based demand pressure with no near-term relief in sight across academic, government, industrial, and biopharma sectors.
Funding Outlook
Weak end-markets and the outlook for National Institutes of Health funding cloud near-term visibility for BRKR.
Revenue Guidance
BRKR lowered the FY25 guide to $3.43-$3.50bn, factoring a weaker than expected academic/government end market along with worsening biopharma, soft demand in China, and adjustments to tariffs.
Bruker (BRKR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.86B
Dividend Yield0.62%
Average Volume (3M)3.39M
Price to Earnings (P/E)66.3
Beta (1Y)1.23
Revenue Growth10.36%
EPS Growth-78.26%
CountryUS
Employees11,396
SectorHealthcare
Sector Strength38
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.32
Shares Outstanding151,531,800
10 Day Avg. Volume3,796,608
30 Day Avg. Volume3,385,652
Financial Highlights & Ratios
PEG Ratio-1.04
Price to Book (P/B)4.90
Price to Sales (P/S)2.59
P/FCF Ratio64.22
Enterprise Value/Market Cap1.78
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit5.23
Enterprise Value/Ebitda33.86
Forecast
1Y Price Target
$46.90Price Target Upside46.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bruker Business Overview & Revenue Model
Company DescriptionBruker Corporation (BRKR) is a global leader in scientific instruments and solutions for molecular and materials research, as well as industrial and applied analysis. The company operates through two main segments: Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). Bruker offers a diverse range of high-performance scientific instruments and analytical solutions, including NMR, mass spectrometry, X-ray diffraction, and imaging systems, among others. These tools are essential for advancing research in life sciences, pharmaceuticals, biotechnology, and materials science.
How the Company Makes MoneyBruker makes money primarily through the sale of its advanced scientific instruments and related services. The company generates revenue from the sale of its high-performance analytical and diagnostic solutions across its key segments. In the Bruker Scientific Instruments (BSI) segment, revenue is driven by the sale of products and services related to life science research, applied markets, industrial and clinical applications. The Bruker Energy & Supercon Technologies (BEST) segment contributes to revenue through the supply of superconducting materials and devices. Additionally, Bruker benefits from ongoing service contracts, maintenance, and support agreements that provide a recurring revenue stream. Strategic partnerships and collaborations with academic, governmental, and industrial institutions also enhance revenue opportunities by driving innovation and expanding the application of Bruker's technologies.
Bruker Earnings Call Summary
Earnings Call Date:Aug 04, 2025
(Q2-2025)
| % Change Since: -15.58%|
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Negative
The earnings call depicted a challenging quarter for Bruker, with significant revenue declines and reduced guidance due to market, tariff, and foreign exchange headwinds. Despite these challenges, Bruker is implementing substantial cost-saving measures and continues to innovate, particularly in diagnostics and new product launches. However, the negative aspects, such as the revenue and EPS decline, along with the challenges in U.S. academic funding, outweigh the positives.Q2-2025 Updates
Positive Updates
Strong Performance in CALID Group
First half '25 CALID Group revenue increased in the low teens percentage with strong growth in microbiology and infection diagnostics driven by the MALDI Biotyper and the Bruker ELITech Molecular Diagnostics business.
Cost Savings Initiative
Bruker announced a significantly expanded cost savings initiative expected to reduce annual costs by $100 million to $120 million for fiscal year 2026.
Innovation and Product Launches
Bruker launched new and market-changing instruments at ASMS, enhancing its competitive position in proteomics and metabolomics.
Resilience in Diagnostic Markets
Strong placements and growth in diagnostics, especially in the ELITech Molecular Diagnostics business, with placements way ahead of plan.
Negative Updates
Revenue Decline
Q2 '25 reported revenues decreased 0.4% year-over-year to $797.4 million, with an organic revenue decrease of 7.0%.
Reduced Guidance
Bruker lowered guidance expectations for fiscal year '25, expecting approximately flat constant exchange rate revenue growth and an organic revenue decline of 2% to 4%.
U.S. Academic Funding Challenges
U.S. academic funding disruptions are anticipated, with budgets possibly being down 20% to 25% for fiscal year '25.
EPS Decline
Q2 '25 non-GAAP EPS was $0.32, down 39% from $0.52 in the second quarter of 2024, impacted by organic revenue decline, tariffs, and foreign exchange headwinds.
Tariff and Currency Headwinds
Higher U.S. tariffs and currency trade winds caused margins and profitability to come in below expectations.
Company Guidance
During Bruker Corporation's Second Quarter 2025 Earnings Conference Call, the company provided updated guidance for the fiscal year 2025, anticipating approximately flat constant exchange rate revenue growth. The organic revenue is expected to decline by 2% to 4% for the year, with non-GAAP EPS projected to decrease by a mid-teens percentage year-over-year. The company faced significant challenges in the quarter due to lower-than-anticipated bookings and revenues, with a book-to-bill ratio in the BSI segment in the mid-0.9 range. Revenue for Q2 2025 was reported at $797.4 million, a 0.4% decrease year-over-year, with a 7% organic decline. Non-GAAP operating margin decreased by 480 basis points to 9%, and non-GAAP EPS was $0.32, down 39% from the previous year. Bruker announced a cost savings initiative aimed at reducing annual costs by $100 million to $120 million by fiscal year 2026, expecting this to enhance margins and potentially lead to double-digit EPS growth even in a muted revenue growth scenario.Bruker Financial Statement Overview
Summary
Bruker's financials reflect strong revenue growth and efficient cash flow management amidst rising costs and increased leverage. While profitability margins have faced some pressure, the company's ability to generate cash supports its financial health. Balance sheet leverage is a potential risk that needs monitoring, but the equity foundation remains stable, suggesting resilience in the face of industry challenges.Income Statement
The company exhibits strong revenue growth with a 14.52% increase from 2023 to 2024 and consistent gross profit margins around 48-50%. However, net profit margins have declined recently from 3.36% TTM (Trailing-Twelve-Months) compared to 3.36% in 2024, indicating increased expenses or cost pressures. EBIT and EBITDA margins are stable yet slightly compressed due to rising operating costs.78
Positive
Balance Sheet
The balance sheet shows a solid equity ratio of approximately 30.62% TTM, reflecting a stable financial base. The debt-to-equity ratio is high at 1.16 TTM, suggesting significant leverage. Although the company has increased its assets, the rise in debt levels could pose risks if not managed carefully.72
Positive
Cash Flow
Cash flow analysis indicates robust operating cash flows relative to net income, with a ratio of 3.70 TTM. Free cash flow showed a strong growth rate of 28.35% TTM, highlighting effective cash management. Despite substantial investment activities, the company maintains positive free cash flow, supporting its operational and strategic initiatives.80
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.44B | 3.37B | 2.96B | 2.53B | 2.42B | 1.99B |
| Gross Profit | 1.65B | 1.65B | 1.51B | 1.31B | 1.21B | 939.80M |
| EBITDA | 255.20M | 438.60M | 599.00M | 545.30M | 497.10M | 320.70M |
| Net Income | 79.60M | 113.10M | 427.20M | 296.60M | 277.10M | 157.80M |
Balance Sheet | ||||||
| Total Assets | 6.34B | 5.81B | 4.25B | 3.62B | 3.65B | 3.05B |
| Cash, Cash Equivalents and Short-Term Investments | 92.00M | 183.40M | 488.30M | 645.50M | 1.17B | 731.80M |
| Total Debt | 2.44B | 2.25B | 1.38B | 1.22B | 1.33B | 891.50M |
| Total Liabilities | 4.47B | 3.99B | 2.84B | 2.49B | 2.57B | 2.07B |
| Stockholders Equity | 1.82B | 1.78B | 1.38B | 1.13B | 1.08B | 975.60M |
Cash Flow | ||||||
| Free Cash Flow | 49.30M | 136.00M | 243.20M | 143.00M | 190.40M | 235.00M |
| Operating Cash Flow | 165.90M | 251.30M | 350.10M | 262.00M | 282.40M | 333.20M |
| Investing Cash Flow | -245.40M | -1.76B | -326.00M | -239.30M | -192.40M | -193.70M |
| Financing Cash Flow | -33.30M | 1.23B | -193.40M | -415.20M | 318.70M | -161.60M |
Bruker Technical Analysis
Negative
32.07
Price Trends
39.65
Negative
39.86
Negative
47.89
Negative
Market Momentum
-1.16
Positive
31.34
Neutral
15.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Negative. The current price of 32.07 is below the 20-day moving average (MA) of 40.29, below the 50-day MA of 39.65, and below the 200-day MA of 47.89, indicating a bearish trend. The MACD of -1.16 indicates Positive momentum. The RSI at 31.34 is Neutral, neither overbought nor oversold. The STOCH value of 15.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRKR.
Bruker Risk Analysis
Bruker disclosed 41 risk factors in its most recent earnings report. Bruker reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bruker Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $5.15B | ― | -91.13% | ― | 22.37% | 31.14% | |
65 Neutral | $3.77B | 46.53 | 5.15% | ― | 7.21% | -23.29% | |
61 Neutral | $2.32B | 30.62 | -17.87% | ― | 8.57% | -1154.64% | |
59 Neutral | $7.21B | 23.20 | 4.59% | ― | -0.33% | ― | |
51 Neutral | $7.39B | 0.42 | -62.86% | 2.37% | 15.61% | -1.93% | |
50 Neutral | $4.86B | 66.28 | 4.43% | 0.62% | 10.36% | -78.26% | |
47 Neutral | $76.77M | ― | -26.20% | ― | 20.81% | -498.66% |
* Healthcare Sector Average
Performance Comparison
BRKR
Bruker
32.07
-31.00
-49.15%
BIO
Bio-Rad Laboratories
272.18
-56.18
-17.11%
ITGR
Integer Holdings
107.72
-6.77
-5.91%
LIVN
LivaNova
42.61
-2.39
-5.31%
XTNT
Xtant Medical Holdings
0.55
-0.10
-15.38%
IRTC
Irhythm Technologies
160.34
89.48
126.28%
Bruker Corporate Events
Executive/Board ChangesShareholder Meetings
Bruker Approves 2026 Incentive Compensation Plan
Neutral
May 29, 2025
Bruker Corporation’s stockholders approved the 2026 Incentive Compensation Plan during the 2025 Annual Meeting held on May 29, 2025. The plan, effective February 19, 2026, will replace the 2016 Incentive Compensation Plan and authorizes up to 12,000,000 shares for issuance. It will be administered by the Compensation Committee and offers various awards to non-employee directors, employees, and key advisors. The plan will terminate on May 28, 2035, unless ended earlier. Additionally, the meeting included the election of directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent auditor for 2025.
The most recent analyst rating on (BRKR) stock is a Hold with a $74.00 price target. To see the full list of analyst forecasts on Bruker stock, see the BRKR Stock Forecast page.
Legal ProceedingsBusiness Operations and Strategy
Bruker Announces Settlement with 10x Genomics
Positive
May 14, 2025
On May 14, 2025, Bruker Corporation announced a global settlement with 10x Genomics to resolve patent disputes, resulting in the dismissal of multiple litigations and the establishment of cross-license agreements. This settlement allows Bruker to focus on its spatial biology platforms, CosMx® and GeoMx®, enhancing research in oncology and neurobiology without legal distractions, thereby benefiting the scientific community and advancing precision medicine.
The most recent analyst rating on (BRKR) stock is a Hold with a $74.00 price target. To see the full list of analyst forecasts on Bruker stock, see the BRKR Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.